---
title: "EMA establishes new group to counter vaccine hesitancy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284779005.md"
description: "The European Medicines Agency (EMA) has established a new advisory group to enhance vaccine confidence amid rising hesitancy in Europe. This group, comprising healthcare professionals, academics, and public health representatives, will meet quarterly as part of the EMA's Vaccine Outreach Strategy. Recent WHO data indicates that childhood vaccination rates remain below pre-pandemic levels, increasing vulnerability to diseases. EMA's Executive Director emphasized the importance of transparent communication to rebuild public trust in vaccines. Sanofi supports this initiative, highlighting the need for coordinated action across European Member States to combat vaccine hesitancy."
datetime: "2026-04-30T13:10:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284779005.md)
  - [en](https://longbridge.com/en/news/284779005.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284779005.md)
---

# EMA establishes new group to counter vaccine hesitancy

The European Medicines Agency (EMA) has launched an advisory group designed to help boost “vaccine confidence” amid growing hesitancy in the region.

This advisory group, which will meet each quarter, is made up of academics, representatives of healthcare professionals, medical societies and patient organizations, as well as public health bodies.

It’s also part of the EMA’s Vaccine Outreach Strategy, a broader approach to enhance the perception of vaccines across Europe.

In data shared by the World Health Organization (WHO) last summer, childhood vaccinations against measles, whooping cough and other diseases in the WHO European Region “remained below pre-pandemic levels in 2024, adding to the number of children left vulnerable to disease and increasing the risk of outbreaks.”

The organization's report found that coverage “ranged widely among countries in the Region in 2024, with decreasing coverage rates of the first dose of the measles, mumps and rubella \[MMR\] vaccine and the third dose of the DTP \[diphtheria, tetanus and polio\] vaccine overall, with some countries reporting a coverage rate of as low as 23% for MMR and 51% for DTP.”

"Vaccine hesitancy is a growing global threat to public health,” said EMA’s Executive Director, Emer Cooke, in an April 29 statement.

“When public trust declines," the statement continued, "infectious diseases can reemerge, putting lives at risk. EMA has a vital role to play in sharing fact-based and transparent data, clearly explaining the science behind vaccine approvals to support informed decision making."

Sanofi, one of the largest vaccine drugmakers in Europe, told Fierce Pharma Marketing that it welcomes the group and its mandate.

“At a time when vaccine hesitancy can undermine progress against infectious diseases, initiatives that promote transparency, science-based communication and public engagement are essential to help protect people's lives,” a Sanofi spokesperson said.

“In addition to these efforts, sustained and coordinated action across European Member States will be critical to rebuild trust, protect communities and save lives.”

### Related Stocks

- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [Omeros Q1 net income turns positive after YARTEMLEA launch](https://longbridge.com/en/news/286310334.md)
- [OS Therapies Reports First Quarter 2026 Financials and Provides Business Update | OSTX Stock News](https://longbridge.com/en/news/286755967.md)
- [Dogecoin reclaims $0.1100: can bulls trigger another rally soon?](https://longbridge.com/en/news/286558043.md)
- [Project helps turn around lives of special needs children and their parents](https://longbridge.com/en/news/286424988.md)
- [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)